Welcome to our dedicated page for Genelux SEC filings (Ticker: GNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page presents Genelux Corporation (NASDAQ: GNLX) SEC filings, offering insight into how the late clinical-stage biopharmaceutical company reports its activities as it develops oncolytic immunotherapies. Genelux focuses on next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by Olvi-Vec (olvimulogene nanivacirepvec), and its regulatory disclosures help investors follow governance, financing, and development-related matters.
Key filing types for GNLX include annual and quarterly reports, which discuss research and development efforts, clinical trial status for programs such as the OnPrime/GOG-3076 Phase 3 ovarian cancer trial, the VIRO-25 Phase 2 NSCLC trial, and the Olvi-Vec-SCLC-202 Phase 1b/2 SCLC trial, as well as risk factors and other business information. Definitive proxy statements (DEF 14A) provide details on board structure, director elections, equity incentive plans, and corporate governance practices, including matters submitted to stockholders at annual meetings.
Current reports on Form 8-K can describe material events such as changes to equity compensation terms, option repricing decisions under the company’s equity plans, or other board-approved actions. Registration statements and prospectus supplements associated with underwritten public offerings of common stock outline how Genelux raises capital to fund research and development, clinical trial expenses, and general corporate purposes.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as clinical program disclosures, equity plan changes, and stockholder voting outcomes. Real-time updates from EDGAR, along with access to ownership and compensation information contained in proxy materials and other filings, allow investors to monitor GNLX’s regulatory reporting as it advances its immuno-oncology pipeline.
Aladar Szalay filed an amended Schedule 13G reporting beneficial ownership of 3,134,286 shares of Genelux Corp common stock, representing 8.2% of the company. This percentage is based on 38,051,771 shares outstanding as of October 30, 2025, as disclosed in Genelux’s Form 10-Q.
The filing shows 1,149,821 shares with sole voting and dispositive power, mainly through two Szalay family trusts, and 1,984,465 shares with shared voting and dispositive power, held by the Szalay Trust dated August 30, 2021 and the reporting person’s spouse. The event date triggering the filing is December 31, 2025.
Genelux Corporation filed a current report outlining an update to its corporate presentation with new business and strategic information. The refreshed presentation, dated February 2026, may be used by management in future meetings and is available in the Investors section of the company’s website.
The presentation is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed for liability purposes under the Exchange Act or incorporated into other securities filings unless specifically referenced.
Genelux Corporation is conducting an underwritten public offering of 6,666,667 shares of common stock at
Genelux Corporation is offering 6,666,667 shares of common stock at $3.00 per share in an underwritten Nasdaq offering. The company expects net proceeds of approximately $18.3 million, or about $21.1 million if the underwriters fully exercise their 1,000,000-share option, after underwriting discounts and expenses. Shares outstanding are expected to rise to 44,713,445, or 45,713,445 if the option is fully exercised, which will dilute new investors compared with the $0.82 pro forma net tangible book value per share. Genelux plans to use the cash for general corporate purposes, including research and development, clinical trials, capital spending and working capital, and believes that, together with existing resources, this funding will support operations for at least 12 months. The prospectus also highlights interim clinical data for Olvi-Vec in lung cancer trials and notes a prior auditor going concern explanatory paragraph.
Genelux Corp’s Chief Medical Officer, Jason Litten, reported a new stock option grant. On 01/02/2026, he received an option to buy 275,000 shares of Genelux common stock at an exercise price of $4.55 per share.
The option vests over time, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in 36 equal monthly installments after that. Following this grant, Litten beneficially owns 275,000 stock options directly.
Genelux Corp's Chief Medical Officer, Jason Litten, filed an initial ownership report on Form 3. The filing identifies him as an officer and confirms that, as of the event date of 01/02/2026, he reports no securities as beneficially owned. The document also includes a power of attorney (Exhibit 24), with the form signed by attorney-in-fact Eric Groen on 01/07/2026.
Genelux Corporation plans a primary offering of common stock under its shelf registration, with Lucid Capital Markets as sole book‑runner. The company expects to use the net proceeds for general corporate purposes, including research and development, clinical trial expenses, capital expenditures and working capital, and may also in‑license or acquire complementary assets.
Genelux is a late clinical‑stage biopharmaceutical company developing oncolytic viral immunotherapies, led by its Olvi‑Vec product candidate. Recent interim data in small cell lung cancer showed 9 evaluable patients with a 33% overall response rate and signs of durability, and in non‑small cell lung cancer 5 evaluable patients with a 60% disease control rate and tumor shrinkage in several patients.
The company highlights that its auditor’s report includes an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern, and it warns investors about immediate and potential future dilution, significant stock price volatility, lack of dividends, and broad discretion over use of proceeds.
Genelux Corporation senior vice president of clinical development reported two sales of company common stock. On August 21, 2025, the reporting person sold 3,219 shares at $3.3574 per share, and on November 17, 2025, an additional 973 shares were sold at $5.3694 per share.
According to the disclosure, these shares were sold to cover estimated taxes related to the vesting of restricted stock units. After the reported transactions, the officer beneficially owned 145,844 shares of Genelux common stock directly.
Genelux Corporation president and CEO Thomas Zindrick reported sales of company common stock primarily to cover estimated taxes related to the vesting of restricted stock units. On August 21, 2025, he sold 12,673 shares of common stock at an average price of $3.3267 per share, and on November 17, 2025 he sold an additional 4,509 shares at $5.3694 per share.
After these transactions, he beneficially owned 538,431 shares of Genelux common stock directly. According to the footnotes, this total reflects the reported sales, transactions reported on a filing dated August 29, 2025, and 1,452 shares acquired under the Issuer's Employee Stock Purchase Plan on November 14, 2025.
Genelux Corporation (GNLX) filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Net loss was $7.95 million for the quarter and $22.9 million for the nine months ended September 30, 2025, as the company recorded $8.2 million in quarterly operating expenses driven by R&D and G&A.
Liquidity remains constrained: cash, cash equivalents, restricted cash and short‑term investments totaled $21.0 million as of September 30, 2025, and net cash used in operations was $19.1 million for the nine months. Management states these resources are expected to fund operations into the third quarter of 2026. The independent auditor previously expressed substantial doubt about the company’s ability to continue as a going concern.
Genelux completed a March 2025 underwritten offering of 3,000,000 shares at $3.50, yielding $9.6 million in net proceeds, and issued an underwriter warrant for 120,000 shares at $4.20. Shares outstanding were 38,046,778 as of September 30, 2025. The company continues advancing Olvi‑Vec, including a Phase 2 NSCLC trial under its Newsoara collaboration.